Infant HIV Transmission or Death at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant HIV Transmission or Death at 6 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
HIV Transmission or Death at 12 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes infant HIV Transmission or Death at 12 months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
1 finding from 1 review
Infant Mortality at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Mortality at 6 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (moderate certainty).
1 finding from 1 review
Infant Mortality at 12 months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Mortality at 12 months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Maternal Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes maternal Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
1 finding from 1 review
Infant Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Prematurity · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes prematurity compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
1 finding from 1 review
Mother to Child Transmission at Birth · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in mother to Child Transmission at Birth compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Mother to Child Transmission at 6 Weeks · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in mother to Child Transmission at 6 Weeks compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Mother to Child Transmission at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora continued: AZT/3TC/LPV‐r may leads to lower mother to Child Transmission at 6 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Mother to Child Transmission at 12 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether kesho Bora continued: AZT/3TC/LPV‐r changes mother to Child Transmission at 12 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
1 finding from 1 review
Low birthweight · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in low Birth Weight compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Stillbirth · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in stillbirths compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review